CYP2C19 genotypes and Helicobacter pylori eradication

被引：7

作者：

Sheu, Bor-Shyang ^{[2
]}

Fock, Kwong-Ming ^{[1
]}

机构：

[1] Changi Gen Hosp, Dept Med, Singapore, Singapore

[2] Natl Cheng Kung Univ, Med Ctr, Dept Internal Med, Inst Clin Med, Tainan 70101, Taiwan

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2008年 / 23卷 / 08期

关键词：

D O I：

10.1111/j.1440-1746.2008.05519.x

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1163 / 1163

页数：1

共 9 条

[1] Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan [J].

Dojo, M ;

Azuma, T ;

Saito, T ;

Ohtani, M ;

Muramatsu, A ;

Kuriyama, M .

DIGESTIVE AND LIVER DISEASE, 2001, 33 (08) :671-675

[2] Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations [J].

Goldstein, JA ;

Ishizaki, T ;

Chiba, K ;

deMorais, SMF ;

Bell, D ;

Krahn, PM ;

Evans, DAP .

PHARMACOGENETICS, 1997, 7 (01) :59-64

[3] Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage [J].

Kang, Jung Mook ;

Kim, Nayoung ;

Lee, Dong Ho ;

Park, Young Soo ;

Kim, Joo Sung ;

Chang, In Jin ;

Song, In Sung ;

Jung, Hyun Chae .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 (08) :1287-1291

[4] Rabeprazole-based eradication therapy for Helicobacter pylori:: a large-scale study in Japan [J].

Kuwayama, H. ;

Asaka, K. ;

Sugiyama, T. ;

Fukuda, Y. ;

Aoyama, N. ;

Hirai, Y. ;

Fujioka, T. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 25 (09) :1105-1113

[5] Current concepts in the management of Helicobacter pylori infection:: the maastricht III consensus report [J].

Malfertheiner, P. ;

Megraud, F. ;

O'Morain, C. ;

Bazzoli, F. ;

El-Omar, E. ;

Graham, D. ;

Hunt, R. ;

Rokkas, T. ;

Vakil, N. ;

Kuipers, E. J. .

GUT, 2007, 56 (06) :772-781

[6]

Malfertheiner P, 2002, ALIMENT PHARM THER, V16, P167, DOI 10.1046/j.1365-2036.2002.01169.x

[7] Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan [J].

Miki, I ;

Aoyama, N ;

Sakai, T ;

Shirasaka, D ;

Wambura, CM ;

Maekawa, S ;

Kuroda, K ;

Tamura, T ;

Kita, T ;

Sakaeda, T ;

Okumura, K ;

Kasuga, M .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (01) :27-33

[8] Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism [J].

Sheu, BS ;

Kao, AW ;

Cheng, HC ;

Hunag, SF ;

Chen, TW ;

Lu, CC ;

Wu, JJ .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (03) :283-288

[9] Metronidazole-resistant Helicobacter pylori in an urban Asian population [J].

Teo, EK ;

Fock, KM ;

Ng, TM ;

Khor, CJL ;

Tan, AL .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2000, 15 (05) :494-497

← 1 →